NCT06940414 Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community
| NCT ID | NCT06940414 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiujuan Zang |
| Condition | Hyperkalemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,890 participants |
| Start Date | 2025-04-28 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,890 participants in total. It began in 2025-04-28 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to investigate the prevalence and risk factors of hyperkalemia in community-based non-dialysis chronic kidney disease (CKD) patients. The main questions it aims to answer are: 1. What is the prevalence of hyperkalemia in non-dialysis CKD patients in a primary care setting? 2. What are the key risk factors influencing the occurrence of hyperkalemia in this population? Researchers will collect clinical and demographic data from participants across 18 community health centers and use both point-of-care testing (POCT) and laboratory-based methods to measure serum potassium levels and related parameters. Participants will: 1. Provide blood samples for POCT and laboratory testing. 2. Participate in interviews or questionnaires to gather clinical and lifestyle information. The findings will be used to construct a risk prediction model for hyperkalemia, aiming to optimize screening pathways and improve disease management strategies in primary care.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older with stable vital signs, specifically defined as: 1. Body temperature: 36.0°C-38.0°C; 2. Pulse: 50-120 beats/min; 3. Respiratory rate: 10-24 breaths/min; 4. Blood pressure: Systolic blood pressure ≥90 mmHg and diastolic blood pressure ≥60 mmHg. * Willing to participate in the study and sign the informed consent form. * Hematocrit (Hct) level between 25% and 60%. * Confirmed diagnosis of chronic kidney disease (CKD). Exclusion Criteria: * Patients in the unstable phase of acute cardiovascular or cerebrovascular diseases (e.g., acute cerebral infarction, cerebral hemorrhage, or acute coronary syndrome). * Patients in the unstable phase of severe acute diabetic complications (e.g., diabetic ketoacidosis or hyperosmolar hyperglycemic coma). * Patients currently in the acute kidney injury (AKI) stage. * Patients who have started renal replacement therapy. * Pregnant or breastfeeding women. * Patients currently participating in or who have participated in other clinical trials within the past six months. * Patients unable to understand verbal or written instructions, including informed consent content. * Patients unable to cooperate with the study procedures. * Other conditions deemed unsuitable for participation in this clinical trial by the investigator.
Contact & Investigator
Xiujuan Zang, MD
PRINCIPAL INVESTIGATOR
Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Frequently Asked Questions
Who can join the NCT06940414 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperkalemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06940414 currently recruiting?
Yes, NCT06940414 is actively recruiting participants. Contact the research team at zangxiujuan@shsmu.edu.cn for enrollment information.
Where is the NCT06940414 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06940414 clinical trial?
NCT06940414 is sponsored by Xiujuan Zang. The principal investigator is Xiujuan Zang, MD at Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 1,890 participants.